Bioventus Inc. 8-K

What Happened
Bioventus Inc. filed a Current Report on Form 8-K on May 6, 2026 to furnish a press release announcing the company’s financial results for the three months ended March 28, 2026. The 8-K cites Item 2.02 (Results of Operations and Financial Condition) and includes the press release as Exhibit 99.1.

Key Details

• Filing date: May 6, 2026; reporting period: quarter ended March 28, 2026.
• Item reported: 2.02 — Results of Operations and Financial Condition; press release furnished as Exhibit 99.1.
• Exhibit included: 99.1 (press release) and 104 (Cover Page Interactive Data File in Inline XBRL).
• Report signed by Anthony D’Adamio, Senior Vice President and General Counsel, on May 6, 2026.

Why It Matters
This 8‑K informs investors that Bioventus has released its latest quarterly earnings and related financial information; the press release (Exhibit 99.1) will contain the specific revenue, earnings, and any company commentary or guidance that can affect valuation and near-term stock performance. Retail investors should review the press release and the company’s full earnings materials (available on the SEC EDGAR site and Bioventus’s investor relations page) to see the actual revenue, net income, EPS, and management discussion referenced by this filing.